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In vivo  imaging  of axonal  transport  in
the sciatic  nerve  of  live  anesthetised
mice.
Signalling  endosomes  are  monitored
using ﬂuorescent  probes  and  confocal
microscopy.
Axonal  transport  in  motor  and sen-
sory neurons  can  be differentiated.
This  method  can  be easily  adapted  to
study the axonal  transport  of  other
cargoes.
Potential  use of  this  in  vivo  imaging
approach  in drug  screening.
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Background:  Axonal  transport  is  essential  for  neuronal  function  and  survival.  Defects  in axonal  transport
have  been  identiﬁed  as  an early  pathological  feature  in  several  disorders  of  the  nervous  system.  The
visualisation  and quantitative  analysis  of axonal  transport  in vivo  in rodent  models  of  neurological  disease
is therefore  crucial  to improve  our understanding  of  disease  pathogenesis  and  for  the  identiﬁcation  of
novel  therapeutics.
New method:  Here,  we  describe  a method  for the  in  vivo  imaging  of  axonal  transport  of signalling  endo-
somes  in the sciatic  nerve  of live,  anaesthetised  mice.
Results:  This  method  allows  the  multiparametric,  quantitative  analysis  of  in  vivo axonal  transport  in motor
and  sensory  neurons  of adult  mice  in control  conditions  and  during  disease  progression.
Comparison  with  existing  methods:  Previous  in  vivo  imaging  of  the  axonal  transport  of  signalling  endo-
somes  has  been  limited  to  studies  in  nerve  explant  preparations  or  non-invasive  approaches  using
magnetic  resonance  imaging;  techniques  that are  hampered  by  major  drawbacks  such  as  tissue  damage
and  low  temporal  and  spatial  resolution.  This  new  method  allows  live  imaging  of  the  axonal  transport
of  single  endosomes  in  the  sciatic  nerve  in situ  and  a more  sensitive  analysis  of  axonal  transport  kinetics
than  previous  approaches.
Conclusions: The  method  desc
axonal  transport  in both  mot
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. Introduction
Neurons are highly polarised cells with axons that can extend
ver a meter away from the cell body in large mammals. This
nique morphology makes neurons particularly reliant on active
ntracellular transport. Long distance ATP-dependent transport
long the axon is predominantly mediated by two families of
icrotubule-associated motor proteins: kinesins and cytoplasmic
ynein (Maday et al., 2014). Axonal transport plays two main roles
n neurons: (1) Supply and clearance: delivery of organelles and
ewly synthesised proteins, lipids and RNA to the axon and distal
ynapses, and removal of faulty ones to the soma for degradation
nd/or recycling; (2) Long-distance communication between the
xon tip and the soma, including the transport of neurotrophic fac-
ors and their activated receptor complexes, which are essential for
urvival (Chowdary et al., 2012). It is therefore not surprising that
lterations in axonal transport can be deleterious to neuronal func-
ion and survival, and that such deﬁcits are proposed to be involved
n the pathogenesis of several neurological diseases, including amy-
trophic lateral sclerosis (ALS) (Bilsland et al., 2010; Kieran et al.,
005), Charcot Marie Tooth type 2 (d’Ydewalle et al., 2011), heredi-
ary spastic paraplegia (Kasher et al., 2009) and diabetic neuropathy
Tomlinson and Mayer, 1984).
Due to the well-documented relationship between mitochon-
rial defects and neurodegenerative disease (Johri and Beal, 2012),
ive imaging of axonal transport in vivo has been previously
escribed for mitochondria (Bilsland et al., 2010; Bolea et al.,
014; Misgeld et al., 2007). However, it is also apparent that an
mpairment of mitochondrial dynamics is not per se necessary
r sufﬁcient to trigger neuronal death in all neurodegenerative
iseases. For example, it has been shown that reversing mitochon-
rial trafﬁcking deﬁcits does not affect neuronal death and disease
rogression in a mouse model of ALS (Zhu and Sheng, 2011). In
ddition, the axonal transport of several other cargoes has been
eported to be affected in neurological diseases, including signalling
ndosomes, autophagosomes, RNA and lysosomes (Millecamps and
ulien, 2013). Importantly, the axonal transport of these cargoes has
een shown to be distinct from that of mitochondria and differen-
ially regulated (Gibbs et al., 2015; Zala et al., 2013), highlighting
he importance of studying their in vivo axonal transport in detail.
Past in vivo imaging of the axonal transport of signalling endo-
omes has been limited to non-invasive approaches using magnetic
esonance imaging (Jouroukhin et al., 2013) or whole body ﬂuores-
ence imaging (Schellingerhout et al., 2009). Such techniques do
ot allow for the analysis of axonal transport in speciﬁc neuronal
ypes, nor permit the real-time visualisation of individual axons
nd endosomes. These shortcomings greatly limit the quantitative
nalysis of in vivo axonal transport and the use of these approaches
or the evaluation of new therapeutic agents aimed at normalising
xonal transport in disease models.
Here, we describe the in vivo imaging of the axonal transport
f single endosomes in motor and sensory neurons of the sciatic
erve in live anaesthetised adult mice. Labelling of endosomes is
chieved using one of two ﬂuorescently tagged probes—the atoxic
inding fragment of tetanus neurotoxin (HCT) (Bercsenyi et al.,
014; Bilsland et al., 2010; Bohnert and Schiavo, 2005; Deinhardt
t al., 2006) or an antibody directed against the extracellular
omain of the p75 neurotrophin receptor (-p75NTR) (Deinhardt
t al., 2007). -p75NTR allows the labelling of endosomes within
75NTR-expressing cells, including sensory neurons and develop-
ng or stressed motor neurons (Ibanez and Simi, 2012; Xie et al.,
003).We  outline the protocol for injection of these ﬂuorescently
agged probes into: (1) the tibialis anterior (TA) and gastrocnemius
uscles (GC) of the hindlimb, allowing labelling of both motor and
ensory axons of the sciatic nerve; and (2) the footpad, allowing force Methods 257 (2016) 26–33 27
the speciﬁc labelling of sensory neurons. Finally, we discuss meth-
ods for the detailed analysis of axonal transport characteristics.
2. Materials and methods
2.1. Reagents
The following reagents are required:
BL21(DE3)pLys Escherichia coli bacteria (Agilent Technologies,
cat. no. 230134), pGEX-4T3 vector (GE Life Sciences, cat. no.
28-9545-52), isopropyl ß-d-1-thiogalactopyranoside (IPTG; Sigma
Aldrich, cat. no. I5502), phosphate buffered saline (PBS; Sigma
Aldrich, cat. no. P4417), Tween® 20 (Sigma Aldrich, cat. no. P9416),
phenylmethylsulfonyl ﬂuoride (PMSF; Fluka-Sigma Aldrich, cat. no.
78830), benzamidine hydrochloride hydrate (Fluka-Sigma Aldrich,
cat. no. 12073), glutathione-agarose (Sigma Aldrich, cat. no. G4510),
human thrombin (Sigma Aldrich, cat. no. T6759), Bradford protein
assay (Bio-Rad, cat. no. 500-0006), tris-(2-carboxyethyl)phosphine
hydrochloride (TCEP; Thermo Scientiﬁc, cat. no. 20490), dimethyl
sulfoxide (DMSO; Sigma Aldrich, cat. no. 41648), AlexaFluor555C2
maleimide (Life Technologies, cat. no. A-20346), AlexaFluor647
antibody labelling kit (Life Technologies, cat. no. A-20186), recom-
binant human BDNF (50 ng/l  in distilled water; Peprotech, cat. no.
450-02), isoﬂurane (National Veterinary Services, UK), 70% ethanol
solution (v/v in distilled water), saline (0.9% NaCl w/v).
2.2. Equipment and software
The following equipment (or similar alternatives) is required:
Superdex 200HR gel ﬁltration column (GE Healthcare, cat. no.
17-1088-01), Amicon Ultra, Ultracel-30K ﬁlter device (Millipore,
UFC803024), PD10 desalting column (GE Healthcare, cat. no. 17-
0851-01), Amicon Ultra-0.5 ﬁlter device (Millipore, UFC505096),
Nanodrop spectrophotometer (Labtech International), Zeiss LSM
780 NLO Multiphoton-prepared confocal microscope, oil immer-
sion 40× objective (Zeiss EC PlnN 40×/1.3 Oil DIC  II), oil immersion
63× objective (Zeiss Plan Apo 63×/1.4 Oil DIC II), immersion oil
ImmersolTM 518 F ﬂuorescence free (cat. no. 444960-0000-000),
tuned damped optical table (Smart Table ST-UT2 Series, New-
port), environmental chamber (Zeiss XL multi S1 DARK LS; cat. no.
411857-9420-000), computer with microscope control and image
acquisition software (Zen System 2012, cat no. 410135-1003-120),
anaesthetic chamber and mask, hair clipper, cotton swabs, thermal
blanket (such as a recirculating warm water or infrared heating
pad), Zeiss Opmi MDU  operating microscope with stand, surgical
tape (3MTM MicroporeTM, cat. no. 1530S-1), scalpel (Swann Morton
no. 15 disposable scalpels, cat. no. 0505), microsyringe (Hamilton,
model 701 RN, 26s gauge/51 mm;  cat. no. 80330), sterile suture
material (PDSTM II 6-0, 45 cm length, needle 3/8 circle; Ethicon),
curved forceps (John Weiss International, Jewellers Forceps, no. 7,
curved, cat. no. 0101374), straight forceps (John Weiss Interna-
tional, Jewellers Forceps, no. 5 straight, very ﬁne, no. 0101472),
scissors, Paraﬁlm®, microscope stage for imaging of small rodents
(custom made for Zeiss LSM 780; Digital Pixel), glass coverslips
(VWR International, 22 mm × 64 mm,  thickness 1.0, cat. no. 631-
0142).
Time-lapse images were analysed using ImageJ software for
kymograph generation (http://imagej.nih.gov/ij/download.html)
and Kinetic Imaging for tracking of individual endosomes (other
similar motion analysis software can also be used).
2.3. Equipment setupThe protocol utilises an inverted confocal microscope (Sup-
plementary Fig. 1) equipped with a 40× EC Plan-Neoﬂuar oil
immersion objective with a numerical aperture (NA) of 1.3 and a
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3× Plan-Apochromat oil immersion objective with a NA of 1.4.
lexaFluor555-conjugated HCT was visualised using the 561 nm
aser line, whilst the AlexaFluor647-conjugated p75NTR antibody
as visualised using the 633 nm laser line.
The microscope is controlled by a computer with appropri-
te software for image acquisition. Ideally, the microscope should
e housed within a darkened environmental chamber with an
ttached heating unit (Supplementary Fig. 1), allowing all equip-
ent to be pre-warmed to 37 ◦C, the mouse’s body temperature
o be stably maintained and outside light to be excluded. The
icroscope stage was replaced with a custom-made stage with a
5 × 18 mm window, covered with a glass coverslip (22 × 64 mm,
hickness no. 1) (Supplementary Fig. 2).
.4. Mice
Mice with a body weight over 17 g are recommended, as the sci-
tic nerve is easier to expose and image in larger mice. Larger mice
re also easier to stably anaesthetise. For reference, the youngest
ge our laboratory has reproducibly imaged is 25 days (Bilsland
t al., 2010).
All animal work was carried out under license from the UK Home
fﬁce in accordance with the Animals (Scientiﬁc Procedures) Act
986 (Amended Regulations 2012).
.5. Preparation of ﬂuorescently labelled HCT and ˛-p75NTR
.5.1. HCT expression and puriﬁcation
HCT (HCT441, residues 875–1315), fused at its amino-terminus
o an improved cysteine-rich tag (FLN CCP GCC MEP) (Martin et al.,
005) and a human inﬂuenza haemagglutinin (HA) epitope (YPY
VP DYA), was expressed as a glutathione-S-transferase (GST)
usion protein in BL21(DE3)pLys E. coli using the pGEX-4T3 vec-
or (Restani et al., 2012). This version of HCT has been optimised
or longer shelf life and low processing by tissue proteases. The
usion protein was expressed for 4 h at 30 ◦C in the presence of
.4 mM IPTG. Bacteria were pelleted, washed with PBS containing
.05% Tween 20 (PBST) and resuspended in resuspension buffer
PBST containing 2 mM EDTA, 0.1% 2-mercaptoethanol, 0.5 mM
MSF and 1 mM benzamidine). The suspension was then subjected
o two cycles of snap freezing and thawing and sonicated three
imes at maximum power for 15 s. The resulting lysate was ultra-
entrifuged at 28,000 rpm for 30 min  The cleared bacterial extract
as incubated with glutathione-agarose beads for 2 h at 4 ◦C. The
ound GST-fusion protein was then washed with PBST, incubated
ith 50 mM tris(hydroxymethyl)aminomethane–HCl (Tris–HCl)
H 7.4, 2 mM ATP, 10 mM MgSO4 for 10 min  at 37 ◦C followed
y PBST containing 0.5 M NaCl. The tagged HCT were released by
hrombin cleavage (20 NIH units of human thrombin in 1 ml  of
0 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.1% 2-mercaptoethanol)
or 30 min  at 25 ◦C, and further eluted in the same buffer with-
ut thrombin containing 500 mM NaCl. The pooled fractions were
oncentrated and puriﬁed by gel ﬁltration on Superdex 200HR equi-
ibrated in 20 mM HEPES-NaOH, pH 7.4, 150 mM NaCl (0.4 ml/min).
urity was assessed by SDS–PAGE and factions containing a mix
f monomeric and dimeric HCT were pooled, concentrated using
micon Ultracel-30K (30,000 Da MWCO) ﬁlters, aliquoted, snap
rozen in liquid nitrogen and stored at −80 ◦C. Protein concentra-
ion was determined by Bradford assay using puriﬁed bovine serum
mmunoglobulins as standard.
.5.2. Fluorescent labelling of HCT with AlexaFluor555
1.5 mg  HCT protein was diluted in labelling buffer (10 mM
EPES-NaOH pH 7.4, 250 mM NaCl) containing 1.5 mM  of the
educing agent TCEP and incubated for 30 min  at 4 ◦C. 1 mg  Alex-
Fluor555 C2 maleimide was reconstituted in 30 l DMSO, andce Methods 257 (2016) 26–33
added under stirring to the reduced HCT (11 l per 100 l of reac-
tion mix). The resulting mixture was incubated at 4 ◦C overnight
in the dark with constant agitation. The labelling reaction was
stopped by addition of 4 mM reduced glutathione in Tris–HCl (pH
8.0) for 30 min. The labelled protein was isolated from free dye
using a PD10 desalting column, equilibrated with ice-cold PBS,
according to the manufacturer’s instructions and then dialysed
over two days against ice-cold dialysis buffer (10 mM HEPES-NaOH,
100 mM NaCl, pH 7.4) at 4 ◦C in the dark. Finally, the labelled protein
was concentrated using an Amicon Ultra-0.5 ﬁlter device accord-
ing to the manufacturer’s instructions. The maximum volume that
can be injected into the TA or GC muscle or footpad is approxi-
mately 2 l; therefore ensure that the concentration of the probe
is ≥6.5 g/l.  AlexaFluor555-conjugated HCT was aliquoted, snap
frozen and stored at −80 ◦C until use.
2.5.3. Fluorescent labelling of the p75NTR antibody with
AlexaFluor647
The antibody used in this protocol (5410) was raised against the
extracellular domain of p75NTR and has been previously described
(Deinhardt et al., 2007). In order to achieve good labelling, the
p75NTR antibody was ﬁrst dialysed in PBS at 4 ◦C under stirring
for 48 h, to remove any contaminating ammonium ions or pri-
mary amines. Next, the antibody was  concentrated to 1 mg/ml
using an Amicon Ultra-0.5 ﬁlter device according to the manufac-
turer’s instructions, as this is the optimal concentration for efﬁcient
labelling. The antibody was then labelled using the AlexaFluor647
monoclonal antibody labelling kit according to the manufacturer’s
instructions. The concentration of the labelled antibody was  deter-
mined using a Nanodrop spectrophotometer and the antibody then
stored at 4 ◦C in the dark for up to 2 months.
2.6. Injection of ﬂuorescently labelled probes
Good labelling of the sciatic nerve was achieved using 13 g
of ﬂuorescently labelled HCT and 50 ng BDNF or 2 g ﬂuores-
cently labelled -p75NTR and 50 ng BDNF. BDNF was  included as
it enhances the uptake of the ﬂuorescently labelled probes into the
nerve (Roux et al., 2006). Injection of HCT into the TA and GC  mus-
cles labelled both motor and sensory neurons within the sciatic
nerve, whilst injection into the footpad allowed selective labelling
of sensory neurons. The use of -p75NTR allows the labelling of
endosomes within p75NTR-expressing cells, including sensory neu-
rons and developing or stressed motor neurons (Ibanez and Simi,
2012; Xie et al., 2003). Intramuscular (i.m.) and footpad injections
were performed in different animals.
2.6.1. Injection of ﬂuorescently labelled probes into the TA and GC
muscles
The ﬂuorescently labelled HCT (or -p75NTR) and BDNF were
mixed just before inducing anaesthesia and kept on ice until the
time of injection. The mouse was  anaesthetised using isoﬂurane
and fur was removed from the right hind limb using clippers. The
animal was placed on a thermal blanket to minimise heat loss
during surgery. Skin in the operating area was then disinfected
using 70% ethanol and the right hind limb was immobilised by
taping the paw to the operating table. Small incisions (∼0.5 mm)
were made through the skin to expose the TA and GC muscles
(Fig. 1A). The Hamilton syringe was  loaded with ﬂuorescently
labelled probe/BDNF and inserted into the centre of the TA mus-
cle (at an angle of 30 degrees from the plane of the table), until
the eye of the needle was just embedded in the muscle. 6.5 g of
AlexaFluor555-conjugated HCT (or 1 g AlexaFluor647-conjugated
-p75NTR) and 25 ng BDNF were slowly co-injected (Fig. 1B). The
needle was left in place for 10 s before being slowly removed, in
order to minimise leakage of the probe. This process was then
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nterior (TA) and gastrocnemius (GC) muscles in one hind leg to expose the muscl
xposed TA muscle. (C) Positioning of the needle for injection of the ﬂuorescently la
epeated for the GC muscle, inserting the needle into the belly of
he muscle (1–2 mm deeper than for the TA muscle), at an angle
f 60 degrees to the plane of the table (Fig. 1C). The skin was then
utured closed and the mouse returned to its cage to recover.
.6.2. Injection of ﬂuorescently labelled probes into the footpad
13 g AlexaFluor555-conjugated HCT (or 2 g AlexaFluor647-
onjugated p75NTR antibody) and 50 ng BDNF were mixed just
efore inducing anaesthesia and kept on ice until the time of injec-
ion. The mouse was anaesthetised using isoﬂurane and placed on thermal blanket to minimise heat loss during surgery. The ﬂuo-
escently labelled probe and BDNF were slowly co-injected into the
ootpad and the needle left in place for 10 s before being removed.
he use of non-topical non-steroidal anti-inﬂammatory drugs is
ig. 2. Surgical exposure of the sciatic nerve for in vivo imaging. (A) An incision is made thr
nd  nerves. (B) The skin around the operating ﬁeld is removed and the sciatic nerve (blac
emoved to reveal the underlying sciatic nerve. (D) The sciatic nerve is separated from the
nserted beneath the sciatic nerve to separate it from underlying tissues, thus facilitating gastrocnemius muscles. (A) Incisions are made through the skin above the tibialis
 Positioning of the needle for injection of the ﬂuorescently labelled probe into the
 probe into the exposed GC muscle.
advised for pain management when injecting into the footpad, in
combination with close monitoring during recovery.
2.7. Surgical exposure of the sciatic nerve at the mid-thigh level
Axonal transport was assessed in the sciatic nerve 4 h after injec-
tion of the ﬂuorescently labelled probes, to allow sufﬁcient time for
uptake of the probe into the nerve and initiation of axonal trans-
port. From our experience, labelling of the sciatic nerve persists up
to at least 24 h after injection (Supplementary Fig. 3).The mouse was re-anaesthetised, placed on a thermal blanket
and an incision made from the hip to the knee of the right hind
leg using a scalpel (Fig. 2A). Using scissors, the skin on both sides
of the incision was  cut away (Fig. 2B) and the overlying muscle
ough the skin between the knee and the hip joint to expose the underlying muscle
k arrow) is visible underneath the muscle, below the femur. (C) Muscle is carefully
 surrounding tissue using a pair of curved forceps. (E) A small piece of Paraﬁlm® is
 the imaging of the nerve.
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Fig. 3. In vivo imaging of the exposed sciatic nerve using confocal microscopy. (A) Correct positioning of the anaesthetised mouse on the microscope stage. (B) The exposed
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eciatic  nerve is carefully placed on the glass coverslip, directly above the microscop
ndosomes within axons. Scale bar, 20 m.  (D) Imaging of a collection of axons at 1
cale  bar, 10 m.
emoved in order to expose the sciatic nerve in the mid-thigh region
Fig. 2B, arrow). The surrounding muscles and connective tissue
ere then carefully cut away from either side of the nerve (Fig. 2C),
voiding any blood vessels that, if cut, would ﬂood the preparation
ith blood making imaging of the nerve very difﬁcult. The sciatic
erve was then separated from the underlying tissue by inserting a
air of curved tweezers underneath the nerve and carefully teasing
t free (Fig. 2D). Finally, a small piece of Paraﬁlm® was inserted
eneath the nerve to separate it from the underlying tissue (Fig. 2E)
nd allow for easier location and imaging of the nerve under the
icroscope.
.8. Live confocal imaging of the exposed sciatic nerve
The anaesthetised mouse was transferred to the microscope
tage (Fig. 3A) within the environmental chamber, both of which
ere pre-warmed to 37 ◦C. A small drop of saline was applied
o the glass coverslip to ensure the sciatic nerve did not dry out
uring imaging. The nerve was then carefully positioned directly
bove the objective, ensuring it made good contact with the glass
overslip (Fig. 3B). The sciatic nerve was located using the 40×
bjective and the 63× objective was used to visualise labelled axons
Fig. 3C and Supplementary Video 1). A pinhole of 1.3 Airy Units
1.2 m section) was used and laser power was kept below 2%
o avoid phototoxicity. An area containing 1–3 labelled axons was
elected and imaged at 100× using digital magniﬁcation (Fig. 3D).
he image frame was approximately 60 m by 15 m and the
ptimal number of pixels was chosen that allowed for the best
esolution to be obtained (700 × 700 pixel). Line averaging of 8
as used to reduce noise. A time series was acquired, collecting
mages every 2–6 s (pixel dwell times between 0.6 and 0.8 s) for
p to 500 frames (Supplementary Video 2). At least three time
eries were collected per experiment, imaging different areas of
he nerve each time. After imaging, the mouse was immediately
uthanised.ctive. (C) Raw image of the sciatic nerve using the 63× objective, showing labelled
llows sufﬁcient time and spatial resolution for individual endosomes to be tracked.
2.9. Analysis of axonal transport movies
Time series images were converted into .avi ﬁles for analysis
using Kinetic Imaging software. The speed of axonal transport was
analysed by determining the distance moved by each endosome
between consecutive frames. Endosomes were only tracked if they
crossed the entire width of the image frame. The speeds of individ-
ual steps are presented as a frequency histogram using a 0.2 m/s
binning interval (Fig. 4A, C–E). Error bars represent standard error
of the mean.
Alternatively, ImageJ can be used to create kymographs from
time series images (Fig. 4B) and the average speed of individual
cargoes determined as the distance moved within the given obser-
vation time (for a detailed description of kymograph generation
and analysis see De Vos and Sheetz, 2007).
In order to determine statistical signiﬁcance of axonal transport
data, the average speed is calculated by taking the mean of the mean
speeds within individual tracks for each biological replicate and a
t-test (2 experimental groups) or ANOVA (> 2 experimental groups)
is performed.
3. Results and discussion
We  have established a live imaging technique that allows visu-
alisation of the axonal transport of individual endosomes in vivo in
the mouse sciatic nerve and differentiation of axonal transport in
motor and sensory neurons. The entire protocol can be undertaken
within a period of 6 h, allowing the rapid collection of robust in vivo
data.
One limitation of this method is the restricted temporal resolu-
tion. This is controlled by the size of the observation ﬁeld, and is a
problem inherent with the use of confocal microscopy. However,
the acquisition of frames every 2–4 s, as described in this protocol,
allows individual endosomes to be resolved whilst still enabling
the easy tracking of a particular endosome from one frame to the
next. The temporal resolution is therefore sufﬁcient to gain high
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Fig. 4. Analysis of axonal transport. (A) A comparison of in vitro and in vivo axonal transport speed distribution curves of HCT-labelled signalling endosomes. The speed proﬁles
reveal that HCT-labelled endosomes move in the intact sciatic nerve at signiﬁcantly faster speeds than those observed in vitro in cultured primary motor neurons. (B) Typical
kymograph generated from a wild type in vivo confocal time series. Scale bar, 10 m.  (C and D) Deﬁcits in axonal retrograde transport of signalling endosomes are present
in  motor but not sensory neurons of the SOD1G93A mouse model of amyotrophic lateral sclerosis (ALS). (C) AlexaFluor555-conjugated HCT was  injected i.m. and retrograde
transport in single axons of the sciatic nerve was assessed in 73-day old wild type and SOD1G93A mice. SOD1G93A mice displayed a signiﬁcant impairment in retrograde
transport compared to wild type controls (p = 0.001); wild type: 161 carriers, n (animals) = 4; SOD1G93A: 185 carriers, n = 5). (D) AlexaFluor555-conjugated HCT was injected
into  the footpad of wild type and SOD1G93A mice (73 d; pre-symptomatic stage) to allow selective labelling of sensory neurons in the sciatic nerve. The speed proﬁles reveal
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uality data on in vivo endosome dynamics. We  also observed that
xonal transport speeds recorded in vivo are signiﬁcantly faster
han those recorded in vitro and show a lesser degree of variability
Fig. 4A), demonstrating the robustness of our protocol in generat-
ng physiologically-relevant and reliable data.
In the protocol described above, we analysed the speed of indi-
idual steps taken by single endosomes and represented this data
s speed distribution proﬁles (Fig. 4A, C–E). This approach allows a
ast amount of data to be presented in a format that is easy to inter-
ret and that can be tested for statistical signiﬁcance. Our analysisng that the deﬁcits seen in the sciatic nerve after i.m. injection of HCT (C) must be
0). (E) A comparison of in vivo axonal transport speeds in the sciatic nerve of wild
 (only sensory axons labelled) (footpad data adapted from Bilsland et al., 2010).
method also allows the contribution of pauses to be considered.
However, it is also possible to present and analyse axonal trans-
port data in a variety of other ways. Analysis of parameters such
as the frequency of motile cargoes (Bilsland et al., 2010; De Vos
and Sheetz, 2007), percentage of stationary cargoes and stop length
(Marinkovic et al., 2012), average speed (De Vos and Sheetz, 2007;
Marinkovic et al., 2012; Zhang et al., 2010) and net displacement
(De Vos and Sheetz, 2007) have been previously described in detail
and could easily be applied to the data generated from our in vivo
imaging approach.
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The live imaging technique described above enables the in vivo
onitoring of alterations in axonal transport in mouse models
f neurological disease. Such analysis has been performed previ-
usly in our laboratory for both the SOD1G93A mouse model of
LS (Bilsland et al., 2010) and the AR100 mouse model of spinal
ulbar muscular atrophy (Malik et al., 2011). Deﬁcits in axonal
ransport were found selectively in motor neurons at a presymp-
omatic stage in the SOD1G93A mouse, and these defects worsened
t an early symptomatic stage (Fig. 4C and D; Bilsland et al., 2010).
hese studies demonstrate the usefulness of our in vivo imaging
rotocol to analyse axonal transport at different disease stages and
hereby gain insights into the role that deﬁcits in axonal transport
ay  play in disease pathogenesis. These results also highlight the
bility of our protocol to differentiate motor and sensory neurons
Fig. 4E) and to determine their individual roles in disease patho-
enesis (Fig. 4C and D; Bilsland et al., 2010). There is still much
ebate over the role of axonal transport defects in neurodegener-
tion, and the ability to image axonal transport in vivo at different
tages of disease progression in both motor and sensory neurons
ill be crucial to solve this controversy. This protocol can also be
sed to investigate the effect of pharmacological treatments on
xonal transport in vivo, in order to identify potential novel thera-
eutics for neurological diseases in which axonal transport defects
ave been implicated.
Finally this protocol allows the detailed study of cargo-speciﬁc
echanisms of axonal transport in vivo. We  foresee that this
ethod could easily be adapted to monitor the axonal transport of
NA (using dyes such as SYTO RNA Select from Life Technologies),
uorescently labelled growth factors (for example, quantum-dot
onjugated BDNF; Xie et al., 2012), autophagosomes (using LC3-
FP mice; Mizushima and Kuma, 2008) and lysosomes (using
ysotrackerTM or other lysosome-speciﬁc dyes; Ho et al., 2014).
tudying the axonal transport of RNA in motor neurons in vivo will
e particularly interesting in ALS, where mutations in RNA bind-
ng proteins implicated in the regulation of RNA axonal transport
ave been found in patients (Alami et al., 2014; Gitcho et al., 2008;
abashi et al., 2008; Kwiatkowski et al., 2009; Sreedharan et al.,
008; Vance et al., 2009).
. Conclusions
This new method for imaging axonal transport in the sciatic
erve of live, anaesthetised mice allows the rapid collection of
eliable in vivo data that will further our understanding of axonal
ransport and its role in neurological diseases.
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